Array reports data from cardiovascular trial with ARRY-797
Array BioPharma announced results from a Phase 2 study of ARRY-797, an oral, selective p38 mitogen-activated protein kinase inhibitor, in patients with lamin A/C-related dilated cardiomyopathy, a rare, degenerative cardiovascular disease caused by mutations in the LMNA gene. August 30, 2016